If you have been told you have fatty liver, the first thing to know is that it is one of the most reversible chronic conditions there is, and the levers that reverse it are ordinary daily ones you already control. Lose around 7 to 10% of your body weight and the fat clears in most people, the inflammation settles, and in some cases even early scarring pulls back.
A Mediterranean way of eating, regular movement, coffee, and cutting sugary drinks each move liver fat on their own, and how consistently you hold to them matters more than which one you pick. Medicines now exist for the inflammatory form, including the first approved drug and the newer weight and diabetes drugs, and they come after the basics for people who have worked at the habits and need more.
This page covers:
- what works
- in what order
- what to do first
- the Chinese medicine reading by pattern
- the signs that need a doctor
Practice Ranking
Every practice we track for Non-Alcoholic Fatty Liver Disease, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
7 practices · 4 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Weight Loss A 10% loss resolved steatohepatitis in about 90%. | Strong | Self-Directed | Free to $$$ | Moderate to Hard | Weeks to Months | |
| 2 | The Mediterranean Diet A Mediterranean diet cut liver fat by about a third even without weight loss, making it the food pattern to start from. | Moderate | Self-Directed | $ to $$ | Moderate | Months to Longer | |
| 3 | Zone 2 Aerobic and resistance exercise both lower liver fat even when body weight does not change, so movement counts on its own. | Moderate | Self-Directed | Free to $$ | Moderate | Weeks to Months | |
| 4 | Whole Foods Cutting added sugar for eight weeks dropped liver fat from about 25% to 17%, and sugary drinks raise the risk of fatty liver with each serving. | Moderate | Self-Directed | $ to $$ | Moderate to Hard | Weeks to Months | |
| 5 | GLP-1 Medications (Ozempic, Wegovy, Mounjaro) Semaglutide resolved steatohepatitis in 63% against 34% on placebo and improved scarring, and tirzepatide reached up to 62%; both trials were funded by their makers, Novo Nordisk and Eli Lilly. | Strong | Pro | $$$ | Easy to Moderate | Weeks to Months | |
| 6 | Caffeine Coffee drinkers, including decaf, had about 35% lower odds of significant liver scarring. | Moderate | Self-Directed | Free to $ | Easy | Days | |
| 7 | Berberine Berberine lowered liver enzymes, liver fat, blood sugar and cholesterol alongside lifestyle change, an early but consistent signal. | Emerging | Supplement | $ | Easy | Days to Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Fatty liver is fat stored inside the liver cells of a person who does not drink heavily. It is the most common chronic liver condition in the world, affecting about one in four adults, and it was renamed MASLD in 2023 to name the metabolic cause behind it. Most people who have it feel completely well. It is usually found by accident, on an ultrasound or on liver blood tests run for something else, because it stays silent until it is advanced.
The reason to act early is that fatty liver sits on a spectrum, and where you are on it is what matters:
- Simple fat, with little or no inflammation, is the widest window and the most reversible. The fat clears in most people who lose weight.
- Steatohepatitis (NASH, or MASH under the new name) is fat joined by inflammation and injury to the cells. This is the form that can progress to scarring over years.
- Fibrosis, or scarring, is the stage that determines long-term outcome. Early fibrosis can still pull back with sustained weight loss.
- Cirrhosis, advanced scarring, needs monitoring for its own complications.
These stages cannot be told apart from how you feel, which is why a raised liver enzyme or a fibrosis score that will not settle gets followed up.
Fatty liver is a whole-body signal. The same insulin resistance that stores fat in the liver drives heart disease and type 2 diabetes, so most people with fatty liver die of a heart attack before the liver ever becomes the problem. Acting on it early protects more than one organ. Two situations do not fit the usual picture and deserve a second look: fatty liver in someone who is not overweight, more common in South and East Asian backgrounds, and any picture where liver enzymes keep climbing. Check both, so another cause is not missed.
What helps the liver
The treatments below are ordered by effort and cost, cheapest and most durable first. The strongest levers are ordinary daily habits, and how consistently you hold to them matters more than which one you pick. Drugs work too, and they come after the basics. The findings graded below are the ones on this page tested most rigorously; the rest of the evidence is described in the ranking that follows.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Measurement And Diagnosis
About one in four adults worldwide have fatty liver
About one in four people worldwide has fat building up in the liver, and for most of them the greater danger to life is heart disease rather than the liver itself.
Pooled global prevalence of non-alcoholic fatty liver disease was 25.24% (95% CI 22.10 to 28.65). Among people with the condition who were biopsied for a clinical reason, 59.10% had steatohepatitis, and cardiovascular disease was a leading cause of death, ahead of liver-specific causes. Measured in: Meta-analysis of 86 studies covering 8,515,431 people across 22 countries, imaging- and biopsy-based. Prevalence varies widely by region and by how the diagnosis was made, and the higher steatohepatitis figure comes from people biopsied because something looked wrong, so it overstates the share across everyone with fat in the liver. The estimate predates the 2023 MASLD renaming.
Who this may not transfer to:A pooled global figure; prevalence runs higher in the Middle East and South America and lower in Africa, so the single number describes the world, not your neighborhood.
The study · 1
Younossi et al., global epidemiology of nonalcoholic fatty liver disease, meta-analytic assessment of prevalence, incidence, and outcomes · Hepatology 2016;64(1):73-84
Liver
Vitamin E improved steatohepatitis in 43% of non-diabetics, against 19% on placebo
In people without diabetes, a daily high dose of vitamin E improved liver inflammation in about 43% of them, compared with 19% taking a dummy pill.
Vitamin E at 800 IU a day improved steatohepatitis in 43% of patients against 19% on placebo over about 2 years (p=0.001), and lowered liver enzymes. Pioglitazone improved several measures too but did not meet the trial's prespecified threshold for the primary endpoint. Measured in: 247 adults with biopsy-proven non-alcoholic steatohepatitis and without diabetes, in the PIVENS randomized placebo-controlled trial. The benefit was shown in people without diabetes; the drug arm and the diabetic population are separate questions. Long-term high-dose vitamin E has been linked in other trials to a small rise in prostate cancer risk in men and to hemorrhagic stroke, so the dose and the person matter, and it is a decision to make with a clinician after the dietary and activity basics.
Who this may not transfer to:Non-diabetic adults with biopsy-proven steatohepatitis; the result does not automatically extend to people with diabetes or to simple fat without inflammation.
The study · 1
Sanyal et al., pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS) · N Engl J Med 2010;362(18):1675-85
Pioglitazone cleared steatohepatitis in about half of people with diabetes or prediabetes, against under 1 in 5 on placebo
In people with diabetes or prediabetes, the drug pioglitazone cleared liver inflammation in about half of them, compared with fewer than one in five on a dummy pill.
Pioglitazone 45 mg daily reached the primary endpoint, a fall of 2 or more points in the activity score without worsening fibrosis, in 58% against 17% on placebo, and resolved steatohepatitis in 51% against 19%, over 18 months. Measured in: 101 adults with prediabetes or type 2 diabetes and biopsy-proven non-alcoholic steatohepatitis, randomized to pioglitazone or placebo alongside a hypocaloric diet. Both groups also followed a reduced-calorie diet, so the drug's effect sits on top of lifestyle change rather than replacing it. Pioglitazone commonly causes some weight gain and fluid retention and is avoided in heart failure, so it is a considered choice for the right person, not a default.
Who this may not transfer to:Studied specifically in people with impaired glucose handling, the group in whom pioglitazone is most relevant; it was layered on a calorie-reduced diet.
The study · 1
Cusi et al., long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus, a randomized trial · Ann Intern Med 2016;165(5):305-15
Semaglutide cleared steatohepatitis in 59% against 17% on placebo, without clearly easing scarring
The GLP-1 drug semaglutide cleared liver inflammation in about 59% of people against 17% on a dummy pill, though it did not clearly improve the scarring that matters most over the long run.
Daily semaglutide 0.4 mg resolved steatohepatitis without worsening fibrosis in 59% against 17% on placebo over 72 weeks. Improvement in the fibrosis stage itself was not significantly different between groups, at 43% against 33%. Measured in: 320 adults with biopsy-proven non-alcoholic steatohepatitis and fibrosis stage 1 to 3, in a phase 2 placebo-controlled trial. The inflammation resolved but the scarring stage did not shift significantly over 72 weeks, which matters because fibrosis is what drives long-term outcome. Nausea and other gut effects were common. This is a drug that comes after the habits, not a substitute for them.
Who this may not transfer to:A phase 2 trial in people with confirmed steatohepatitis and early-to-moderate fibrosis; it shows resolution of inflammation, with the harder fibrosis endpoint still open.
The study · 1
Newsome et al., a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis · N Engl J Med 2021;384(12):1113-24
Resmetirom cleared steatohepatitis in a quarter to a third and eased scarring in about a quarter
Over a year the newer drug resmetirom cleared liver inflammation in roughly a quarter to a third of people and eased scarring in about a quarter, both better than a dummy pill, though most people on it did not reach either mark.
Over 52 weeks, steatohepatitis resolved without worsening fibrosis in 25.9% (80 mg) and 29.9% (100 mg) against 9.7% on placebo, and fibrosis improved by at least one stage in 24.2% and 25.9% against 14.2% on placebo. Both endpoints were met. Measured in: 966 adults with biopsy-confirmed steatohepatitis and fibrosis stage 1 to 3 in the MAESTRO-NASH phase 3 trial. This is the drug behind the 2024 approval, and it is the first to move both inflammation and fibrosis in a phase 3 trial, though most participants on the drug still did not reach either endpoint, and it was studied on top of standard lifestyle advice rather than instead of it. Long-term outcome data, whether it prevents cirrhosis and death, is still being gathered.
Who this may not transfer to:Studied in confirmed steatohepatitis with fibrosis; it is not a treatment for simple fat without inflammation, and it was added to, not instead of, lifestyle change.
The study · 1
Harrison et al., a phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH) · N Engl J Med 2024;390(6):497-509
Semaglutide resolved steatohepatitis in 63% vs 34% and improved scarring in 37% vs 22% (phase 3)
In the large phase 3 trial the higher dose of semaglutide cleared liver inflammation in about 63% of people, against 34% on a dummy pill, and this time it also eased the scarring, in about 37% against 22%.
At week 72, steatohepatitis resolved without worsening of fibrosis in 62.9% on weekly semaglutide 2.4 mg against 34.3% on placebo (a 28.7 point difference, P<0.001), and fibrosis improved by at least one stage without worsening of steatohepatitis in 36.8% against 22.4% on placebo (a 14.4 point difference, P<0.001). Weight fell by 10.5% against 2.0%. Measured in: Interim 72-week biopsy analysis of the first 800 of 1,197 adults with biopsy-confirmed steatohepatitis and fibrosis stage 2 or 3, randomized to weekly semaglutide 2.4 mg or placebo, in the phase 3 ESSENCE trial. This phase 3 trial reached both endpoints, including the fibrosis improvement that the earlier phase 2 trial had left open, in a much larger group. It is an interim biopsy analysis at 72 weeks within a study that continues to 240 weeks for clinical outcomes, so whether it prevents cirrhosis and death is still being measured. Gastrointestinal effects were more common on the drug. It sits on top of the diet and activity work, and it was studied alongside lifestyle advice.
Who this may not transfer to:The 72-week biopsy result comes from the first 800 participants of a 1,197-person trial; it confirms that both the inflammation and the scarring move, with the long-term clinical-outcome phase still running to 240 weeks.
The study · 1
Sanyal et al., phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE) · N Engl J Med 2025;392(21):2089-2099
Losing 10% of body weight cleared steatohepatitis in about 90%, eased scarring in 45%
People who lost at least a tenth of their body weight over a year cleared the liver inflammation in about nine cases out of ten, and scarring eased in almost half; the more weight lost, the better the result.
Among people who lost 10% or more of their body weight over 52 weeks of lifestyle change, steatohepatitis resolved in 90%, fibrosis regressed in 45%, and all of them had some reduction in the NAFLD activity score. Benefit tracked the amount lost: resolution of steatohepatitis was far less common below 5% loss. Measured in: 293 patients with biopsy-proven non-alcoholic steatohepatitis who underwent a second liver biopsy after 52 weeks of a diet and exercise program. What could explain it instead: Self-selection by success. Whatever lets a person lose 10% of their weight in a year, more support, better health, more resources, may independently favor liver recovery, so the achieved-weight-loss gradient would look similar even if part of the effect were not the weight itself.. This is a single-arm study with no control group, so the whole cohort was trying to change at once and the comparison is between those who succeeded and those who did not. Only about a third reached 5% loss and roughly 1 in 10 reached 10%, so the striking numbers rest on the minority who managed the hardest target.
Who this may not transfer to:A Cuban cohort with biopsy-confirmed steatohepatitis, so the reversal figures describe the inflammatory form specifically, and the achievers were a self-selected minority.
The study · 1
Vilar-Gomez et al., weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis · Gastroenterology 2015;149(2):367-78
A Mediterranean diet cut liver fat by about a third without weight loss
Eating a Mediterranean diet cut the fat stored in the liver by around a third compared with a low-fat, high-carb diet, even when people did not lose any weight.
A Mediterranean diet reduced liver fat measured by magnetic resonance spectroscopy by about 39% relative to a low-fat, high-carbohydrate diet, and improved insulin sensitivity, over 6 weeks in a crossover design where weight was held stable. Measured in: 12 non-diabetic adults with biopsy-proven non-alcoholic fatty liver disease, each acting as their own control across the two diets. A very small crossover study of 12 people over a short period, with weight deliberately kept constant, so it shows the diet pattern moves liver fat on its own but not how large or durable the effect is at scale. Larger pooled trials since then agree on the direction while showing more modest average changes.
Who this may not transfer to:Twelve people is a proof-of-mechanism sample, not a population estimate; read it as showing the pattern can move liver fat independent of weight, not as a precise effect size.
The study · 1
Ryan et al., the Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease · J Hepatol 2013;59(1):138-43
Exercise lowered liver fat even when body weight did not change
Regular exercise lowered the fat in the liver even when body weight stayed the same, so the benefit does not depend on the scale moving.
Pooling trials where diet and body weight were held steady, exercise on its own lowered the fat stored in the liver and improved related clinical markers, so the benefit does not depend on the scale moving. Measured in: Systematic review and meta-analysis of randomized controlled trials of exercise interventions in people with non-alcoholic fatty liver disease, restricted to trials without significant weight loss or dietary change. The individual trials are mostly small and short, and total weekly volume, intensity and adherence varied between them, so the pooled result confirms a direction more firmly than it pins a dose. Exercise moves liver fat further and faster when weight also comes down.
Who this may not transfer to:Pooled across trials that deliberately excluded weight loss, so it isolates the movement itself; the everyday case, moving and losing weight together, does better than either alone.
The study · 1
Babu et al., positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters, a systematic review and meta-analysis · Nutrients 2021;13(9):3135
Coffee drinkers had about 35% lower odds of significant liver scarring
People with fatty liver who drank coffee were about a third less likely to have serious liver scarring. Whether coffee drinkers were any less likely to get fatty liver at all is unsettled: the same analysis found no significant difference there.
Pooling observational studies, coffee drinkers with fatty liver had about 35% lower odds of significant liver fibrosis (RR 0.65, 95% CI 0.54-0.78). Coffee was not significantly associated with a lower chance of developing fatty liver in the first place, or with how common it was. Measured in: Systematic review and meta-analysis of observational studies of coffee consumption in relation to non-alcoholic fatty liver disease incidence, prevalence and fibrosis. These are observational studies pooled together, so they show association rather than proof of cause: coffee drinkers may differ from non-drinkers in ways not fully measured, and the amount and type of coffee were recorded differently across studies. It supports keeping a coffee habit, not starting a heavy one for the liver.
Who this may not transfer to:The signal is for regular coffee, not decaffeinated alone or sugary coffee drinks, and it is an association across populations rather than a measured dose response.
The study · 1
Ebadi et al., effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis, systematic review with meta-analysis of observational studies · Nutrients 2021;13(9):2947
Cutting added sugar for 8 weeks dropped liver fat from about 25% to 17%
In teenage boys, eight weeks of cutting out added sugar dropped liver fat from about 25% to 17%, while it barely changed on the usual diet.
A diet low in free sugar (under 3% of daily calories) for 8 weeks cut liver fat measured by MRI from 25% to 17%, against essentially no change on the usual diet (21% to 20%), a significant difference favoring the sugar restriction. Measured in: 40 adolescent boys aged 11 to 16 with biopsy- or imaging-confirmed non-alcoholic fatty liver disease, randomized to a low-free-sugar diet delivered to their homes or their usual diet. The intervention diet was prepared and delivered to the families, which is more support than a family would usually have, and the trial ran only 8 weeks in a specific group, adolescent boys, so the exact number may not carry to adults or women. The direction, that added sugar drives liver fat, is well supported by the underlying biology.
Who this may not transfer to:Studied only in adolescent boys with meals provided; the mechanism, fructose being converted to liver fat, applies broadly, but this precise effect size is not confirmed in adults or in girls and women.
The study · 1
Schwimmer et al., effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys, a randomized clinical trial · JAMA 2019;321(3):256-65
Five years after weight-loss surgery, steatohepatitis had cleared in about 84%
Five years after weight-loss surgery, liver inflammation had cleared in about 84% of people and the scarring had eased in most of them, including some severe cases.
Five years after bariatric surgery, steatohepatitis had resolved without worsening of fibrosis in 84% of patients with a repeat biopsy, and fibrosis had regressed in a majority, including reversal of some cases of advanced fibrosis. Measured in: 180 severely obese adults with biopsy-proven non-alcoholic steatohepatitis followed for 5 years after bariatric surgery, with serial liver biopsies. What could explain it instead: No control group and loss to follow-up. The people who returned for a 5-year biopsy are plausibly those doing better, and the surgery drives large sustained weight loss whose liver benefit cannot be separated from the operation itself.. This is a single-arm surgical cohort without a randomized comparison group, and only a subset had a full set of biopsies at 5 years, so the resolution figure describes those followed to the end rather than everyone who started. Surgery carries its own operative and long-term nutritional consequences that sit outside this liver endpoint entirely.
Who this may not transfer to:A severely obese surgical cohort; the liver results are among the best reported, but they come with the risks and lifelong changes of the surgery and are not a lifestyle comparison.
The study · 1
Lassailly et al., bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis · Gastroenterology 2020;159(4):1290-1301
Tirzepatide resolved steatohepatitis in up to 62% of people vs 10% on placebo (phase 2)
The dual-hormone drug tirzepatide cleared liver inflammation in roughly half to two-thirds of people, against one in ten on a dummy pill, and eased scarring in about half, against roughly a third on placebo.
Over 52 weeks, steatohepatitis resolved without worsening of fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) against 10% on placebo (all P<0.001), and fibrosis improved by at least one stage without worsening of steatohepatitis in 51 to 55% across the three doses against 30% on placebo. Measured in: 190 adults with biopsy-confirmed steatohepatitis and moderate to severe fibrosis (stage F2 or F3) randomized to weekly tirzepatide (5, 10 or 15 mg) or placebo, with 157 evaluable second biopsies at 52 weeks, in the phase 2 SYNERGY-NASH trial. This is a phase 2 dose-finding trial of about 190 people over a single year, so it establishes that the drug moves both inflammation and scarring while the larger phase 3 confirmation and long-term outcome data are still being gathered. Gastrointestinal effects such as nausea were the most common events, mostly mild to moderate. It is a drug that comes after the habits, and it was studied alongside standard lifestyle advice.
Who this may not transfer to:A phase 2 trial in confirmed steatohepatitis with moderate to severe fibrosis; it shows both the inflammation and the scarring endpoints moving, with phase 3 confirmation of durability and hard outcomes still in progress.
The study · 1
Loomba et al., tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH) · N Engl J Med 2024;391(4):299-310
Sugary drinks raised the risk of developing fatty liver, more with each serving
People who drank sugary beverages more often were more likely to develop fatty liver over six years, and the risk rose the more they drank.
Over 6 years of follow-up, people who drank sugar-sweetened beverages more often had higher odds of new and prevalent fatty liver than those who rarely did, with the risk rising as intake rose. Measured in: Adults in the Framingham Heart Study Offspring and Third Generation cohorts, followed with liver fat assessed by CT and diet by questionnaire. What could explain it instead: People who drink a lot of sugary beverages tend to eat more calories overall, weigh more, and move less, and those factors also cause fatty liver, so part of the association reflects the whole dietary and lifestyle pattern rather than the drink in isolation.. An observational cohort, so it shows that sugary-drink intake travels with fatty liver, not that it is the sole cause. Diet soda, by contrast, was not clearly protective, which fits the idea that the surrounding diet and body weight carry much of the signal.
Who this may not transfer to:A predominantly white US community cohort; the direction is consistent with trial data on sugar, but the exact risk is specific to this population.
The study · 1
Park et al., sugar-sweetened beverage, diet soda, and nonalcoholic fatty liver disease over 6 years, the Framingham Heart Study · Clin Gastroenterol Hepatol 2022;20(11):2524-32
Berberine lowered liver enzymes, liver fat, blood sugar and cholesterol alongside lifestyle change
Berberine, the active compound in the bitter herb Coptis, improved liver enzymes, lowered liver fat, and helped blood sugar and cholesterol, usually alongside lifestyle changes.
Pooling randomized trials, berberine improved liver enzymes, reduced liver fat, and improved insulin resistance and blood lipids compared with control, often alongside lifestyle advice. Measured in: Meta-analysis of randomized controlled trials of berberine in adults with non-alcoholic fatty liver disease. The trials are mostly small, short, and run in China with varied quality and dosing, so the pooled benefit is promising rather than settled, and long-term and biopsy outcomes are missing. Berberine can lower blood sugar and interacts with several medications, so it belongs with a practitioner rather than self-stacked. It is the active compound in Coptis (Huang Lian), a bitter cold herb Chinese medicine uses to clear damp-heat, which fits the robust, inflamed presentation and not the tired, Spleen-deficient one.
Who this may not transfer to:Pooled largely from Chinese trials of varying quality; the direction is consistent but the effect size and durability are not yet confirmed in large, long, biopsy-based studies.
The study · 1
Nie et al., the clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease, a meta-analysis and systematic review · J Transl Med 2024;22(1):225
Milk thistle modestly lowered liver enzymes, with little reliable effect on liver fat
Milk thistle modestly lowered liver enzymes in the blood, with a smaller and less reliable effect on the fat in the liver itself.
Pooling randomized trials, silymarin modestly lowered the liver enzymes ALT and AST compared with control, with smaller and less consistent effects on liver fat itself. Measured in: Systematic review and meta-analysis of randomized controlled trials of silymarin in people with non-alcoholic fatty liver disease or steatohepatitis. The effect on enzymes is modest, and enzymes are a rough marker rather than proof the underlying disease is reversing; the harder outcomes, inflammation and fibrosis on biopsy, are not established. Milk thistle has a long traditional record for the liver and a good safety profile, which is part of why it keeps being studied; it is a reasonable adjunct, not a replacement for the weight, diet and activity work.
Who this may not transfer to:Pooled trials use different silymarin preparations and doses, so the enzyme benefit is a class signal rather than a guide to one specific product.
The study · 1
Li et al., administration of silymarin in NAFLD/NASH, a systematic review and meta-analysis · Ann Hepatol 2024;29(2):101174
Weight loss, the single biggest lever
Fatty liver responds to weight loss more reliably than almost any other chronic condition responds to anything. In a study that biopsied the liver before and after, people who lost 10% or more of their body weight over a year cleared the steatohepatitis in about 90% of cases, and early scarring pulled back in 45%. The more weight came off, the better the result.
The practical target most people are given is 7 to 10% of body weight. Lose it steadily: very rapid loss from a crash diet can briefly inflame the liver.
The fat is not permanent. When the weight comes off, the liver repairs.
A Mediterranean pattern of eating
A Mediterranean way of eating, built on olive oil, fish, vegetables, legumes and whole grains, has the most consistent liver signal of any eating pattern. In a crossover trial it cut liver fat by around a third against a low-fat, high-carbohydrate diet, and it did so even when people lost no weight, while also improving insulin sensitivity. The pattern lowers liver fat from the first week, before the scale has moved.
Movement, aerobic and resistance
Exercise lowers liver fat whether or not you lose weight, so it earns its place from the first week regardless of what the scale does. Aerobic activity, including something as ordinary as brisk walking, lowers liver fat directly. Resistance work does too, and it builds the muscle that clears most of the glucose the liver would otherwise store as fat, which also makes it easier on the joints for someone carrying extra weight. Whichever kind you will keep doing is the one that works.
Coffee
People with fatty liver who drink coffee have less liver fat and less scarring. Pooled across studies of people who already have fatty liver, coffee drinkers had about 35% lower odds of significant fibrosis (RR 0.65, 95% CI 0.54-0.78). Whether coffee also lowers the chance of getting fatty liver in the first place is unsettled: the same analysis found no significant difference there. The signal looks like caffeine and the other coffee compounds together, so keep the habit if you have it. It is not a reason to start drinking large amounts. See the coffee and caffeine page for how much, and how it lands elsewhere in the body.
Cutting sugary drinks and added sugar
The liver turns fructose straight into fat, which makes sugary drinks the first thing to drop. When teenage boys with fatty liver cut added sugar for eight weeks, the fat in their livers fell from about 25% to 17%, while it barely moved on their usual diet. Following people over six years points the same way: those who drank sugar-sweetened beverages more often were more likely to develop fatty liver, and the risk rose with each extra serving. Swapping sweetened drinks for water or unsweetened coffee is one of the highest-return single changes on this list.
Treating what travels with it
Fatty liver rarely occurs alone. Blood sugar, blood pressure, cholesterol and poor sleep usually come with it, and because the heart is the bigger long-term risk, treating these is part of treating the liver. Getting these numbers into range often needs a clinician and a plan of its own.
The medicines, after the basics
Medicines for fatty liver arrived only recently, and they come after the habits above, which work without side effects and hold up after you stop. They are options for someone who has worked at the basics and needs more. Every one was studied alongside diet and activity, added to that work.
The first drug approved for the inflammatory form, resmetirom (Rezdiffra), was cleared in 2024. The weight and diabetes drugs do more:
- Resmetirom cleared steatohepatitis in roughly a quarter to a third of people over a year and eased scarring in about a quarter, both better than a dummy pill, though most people on it reached neither mark.
- Semaglutide, a GLP-1 drug, cleared the inflammation in about 59% of people against 17% on placebo in its phase 2 trial, which left the scarring question open. The larger phase 3 trial (ESSENCE) then closed it: at 72 weeks the higher dose cleared steatohepatitis in about 63% of people against 34% on placebo, and this time also eased the scarring, in about 37% against 22%, with weight down 10.5% against 2.0%.
- Tirzepatide, which acts on two gut hormones, moved both endpoints in its phase 2 trial (SYNERGY-NASH): steatohepatitis resolved in 44 to 62% across three doses against 10% on placebo, and scarring improved in 51 to 55% against 30%.
Both incretin trials are still gathering the long-term outcome data, so whether these drugs prevent cirrhosis and death is being measured now. Nausea is their most common side effect.
Two older drugs have a place in specific people. Pioglitazone cleared steatohepatitis in about half of people with diabetes or prediabetes, against fewer than one in five on placebo, and is a considered option in that group. Vitamin E, at a high daily dose, improved the inflammation in about 43% of people without diabetes against 19% on placebo, which makes it an option for that narrower group, weighed with a clinician for its own long-term safety questions. For people with severe obesity, bariatric surgery does more than any of these: five years on, the inflammation had cleared in about 84% and the scarring had eased in most, including some severe cases.
Two herbal compounds come up often and sit at the emerging end of the evidence. Berberine, the bitter compound in Coptis (Huang Lian), lowered liver enzymes and liver fat and helped blood sugar and cholesterol, usually alongside lifestyle change. Silymarin (milk thistle) modestly lowered liver enzymes in the blood, with a smaller and less reliable effect on the fat in the liver itself. Neither is a substitute for the levers above, and the caution in the Chinese medicine section about adulterated liver products applies to both when bought online.
What To Do First
None of this needs a prescription to begin, and the order matters less than doing a few of them steadily for a few months. The first steps are the low-effort wins; weight loss is what they add up to over time.
The liver turns fructose straight into fat, so sweetened drinks are the first thing to go. Swapping them for water, plain tea or unsweetened coffee is the single change with the fastest visible effect on liver fat, and it costs nothing.
If you already drink coffee, keep it. Coffee drinkers have less liver fat and about 35% lower odds of significant scarring. This is a habit to protect, not a reason to start drinking large amounts.
Exercise lowers liver fat even when the scale does not move, so it earns its place from the first week. Brisk walking counts, and adding some resistance work builds the muscle that soaks up the sugar the liver would otherwise store as fat.
Build meals on olive oil, fish, vegetables, legumes and whole grains. This is the eating pattern with the most consistent liver signal, and it lowers liver fat even before much weight comes off.
This is the biggest lever, and it is the sum of the steps above held over months. Lose it steadily, because losing weight too fast can briefly inflame the liver.
A fibrosis score (FIB-4) from a blood panel is the finding that predicts long-term outcome. Direct-to-consumer lab panels will run liver enzymes and a FIB-4 on your own schedule if your clinician has not, so you can watch the trend that matters.
Go Deeper
- Coffee and caffeine: why coffee tracks with less liver fat and less scarring, how much, and how it lands in the rest of the body.
- Mediterranean diet: the eating pattern with the most consistent liver signal, and how to build it plate by plate.
- Whole foods: the shift away from ultra-processed food and added sugar that sits underneath the whole plan.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine has no category called fatty liver, and reads the picture through the Liver and Spleen. The Spleen in this system governs how food is transformed and moved; when it is overwhelmed by rich, sweet, greasy food and too little movement, dampness and phlegm accumulate, and that stagnant, greasy accumulation is a fair traditional description of what a fatty liver looks like. The same excess and the same sedentary comfort drive both readings. Read the patterns below as an interpretive lens on constitution and habit, not as a map of your liver enzymes or your fibrosis score. Chinese medicine would add a caution of its own: the cold, bitter, Liver-draining herbs suit a damp-heat, robust picture, and they are the wrong direction for the many people whose picture is Spleen deficiency, tiredness after eating, loose stools and a pale swollen tongue, where the aim is to strengthen transformation. Herbal liver products bought online have a documented history of adulteration and of causing the very liver injury they claim to prevent, so any herbs belong with a practitioner and a traceable supply.
Fullness or discomfort under the right ribs, bloating, irritability, tiredness after eating, stools that loosen under stress. The classical direction is to move Liver Qi and strengthen the Spleen so transformation resumes.
A heavier, more inflamed picture: fullness, a bitter taste, a greasy yellow tongue coat, sometimes a flushed complexion, often in a robust body. The direction is to clear damp-heat and free the Liver and Gallbladder.
A long-standing, heavier accumulation with a dull fixed ache, a dusky tongue, and often the metabolic syndrome alongside. The direction is to transform phlegm, resolve damp, and invigorate the Blood, the pattern that maps loosely to fibrosis territory.
When to See Someone
Most of managing fatty liver is quiet, steady work you drive yourself, and testing you can arrange without waiting on anyone: direct-to-consumer lab panels will run liver enzymes and a fibrosis score (FIB-4) on your own schedule if your clinician has not. These are the signs that do warrant a doctor, some of them the same day:
- Yellowing of the skin or the whites of the eyes (jaundice), which points to the liver struggling to keep up and needs assessment(seek urgent care)
- Vomiting blood, or black tarry stools, which can signal bleeding from veins backed up by liver scarring and is an emergency(seek urgent care)
- A belly swelling with fluid, or new confusion, drowsiness or a flapping tremor of the hands, which are signs of advanced liver disease and need same-day care(seek urgent care)
- Right-upper-abdominal pain that is severe or comes with fever, which is a different problem from fatty liver and needs to be looked at
- A fibrosis score (FIB-4) or elastography result in the higher range, which is the finding that actually predicts outcome and warrants a specialist referral
- Liver enzymes that keep climbing, or a new drop in appetite and unplanned weight loss, which need assessment rather than watchful waiting
- Rapid weight loss from a crash diet alongside worsening liver blood tests, since losing weight too fast can briefly inflame the liver
None of this is meant to alarm you. Fatty liver is one of the more reversible chronic conditions, and most people never reach the advanced stages. Knowing the warning signs is simply so nothing is missed while you work at the daily habits that reverse it.
Common Questions
I was told I have fatty liver. Should I worry?
For most people it is a signal to act early. Fatty liver is the most common liver condition in the world, about one in four adults have it, and simple fat in the liver clears in most people who lose weight. What decides the long-term picture is whether inflammation and scarring have set in, which is why the useful next step is a fibrosis score (FIB-4). The greater everyday danger for most people with fatty liver is the heart, so acting on it protects more than the liver.
What is the single most effective thing I can do?
Lose around 7 to 10% of your body weight, steadily. In a study with liver biopsies before and after, people who lost 10% or more cleared the steatohepatitis in about 90% of cases and saw early scarring pull back in 45%. Nothing else on this page matches that. If a full 10% feels far off, the sugary-drink cut and daily movement both lower liver fat on their own and are the easiest places to start.
Can fatty liver actually be reversed?
Yes, more reliably than most chronic conditions. The fat clears in most people who lose weight, the inflammation settles, and in some cases even early scarring regresses. The window is widest before advanced scarring sets in, which is the reason to act while it is still silent, because there usually are no symptoms until late.
Does coffee really help my liver?
The signal is consistent. People with fatty liver who drink coffee have about 35% lower odds of significant scarring. The effect looks like caffeine and the other coffee compounds together. If you already drink it, keep it; it is not a reason to start drinking large amounts, and the caffeine page covers where it helps and where it costs.
Do I need medication?
Most people do not, at least not for the liver directly. The habits above are the main treatment, and medicines come after the basics for people who have worked at them and need more. When they are used, resmetirom is the first drug approved for the inflammatory form, the GLP-1 drug semaglutide and the dual-hormone drug tirzepatide both cleared inflammation and eased scarring in trials, and pioglitazone and vitamin E have a place in specific groups. Any of these is a shared decision with a clinician, weighed on side effects and long-term safety as much as on benefit.
Is it still a risk if I am not overweight?
It can be. Fatty liver in someone who is not overweight is more common in South and East Asian backgrounds, and it still tracks with insulin resistance. A normal weight, or a normal liver enzyme, can both miss it, so thin does not mean safe. The same metabolic levers help. Check that another cause, such as a thyroid problem or a medication, is not being missed.
What is the difference between NAFLD and MASLD?
They are the same condition under two names. It was renamed MASLD in 2023 to name the metabolic cause behind it. The inflammatory form, once called NASH, is now MASH. Nothing about the condition changed; the name was updated to point at the cause.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 16 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.